TY - JOUR
T1 - Rationale and design of the African Cardiomyopathy and Myocarditis Registry Program
T2 - The IMHOTEP study
AU - for the IMHOTEP Investigators
AU - Kraus, Sarah M.
AU - Shaboodien, Gasnat
AU - Francis, Veronica
AU - Laing, Nakita
AU - Cirota, Jacqui
AU - Chin, Ashley
AU - Pandie, Shahiemah
AU - Lawrenson, John
AU - Comitis, George A.M.
AU - Fourie, Barend
AU - Zühlke, Liesl
AU - Wonkam, Ambroise
AU - Wainwright, Helen
AU - Damasceno, Albertino
AU - Mocumbi, Ana Olga
AU - Pepeta, Lungile
AU - Moeketsi, Khulile
AU - Thomas, Baby M.
AU - Thomas, Kandathil
AU - Makotoko, Makoali
AU - Brown, Stephen
AU - Ntsekhe, Mpiko
AU - Sliwa, Karen
AU - Badri, Motasim
AU - Gumedze, Freedom
AU - Cordell, Heather J.
AU - Keavney, Bernard
AU - Ferreira, Vanessa
AU - Mahmod, Masliza
AU - Cooper, Leslie T.
AU - Yacoub, Sir Magdi
AU - Neubauer, Stefan
AU - Watkins, Hugh
AU - Mayosi, Bongani M.
AU - Ntusi, Ntobeko A.B.
AU - Mwita, Julius
AU - El-Guindy, Ahmed
AU - Kola, Tolno Sandy
AU - Barasa, F. Ayub
AU - Ogah, Okechukwu
AU - Russell, James
AU - Pandie, Shaheen
AU - Cupido, Blanche
AU - De Decker, Rik
AU - Brink, Paul
AU - Heradien, Marshall
AU - Makubalo, Nomlindo
AU - Nxele, Mahlubandile
AU - Longo-Mbenza, Benjamin
AU - Suliman, Ahmed
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/6/15
Y1 - 2021/6/15
N2 - Background: Heart failure (HF), the dominant form of cardiovascular disease in Africans, is mainly due to hypertension, rheumatic heart disease and cardiomyopathy. Cardiomyopathies pose a great challenge because of poor prognosis and high prevalence in low- and middle-income countries (LMICs). Little is known about the etiology and outcome of cardiomyopathy in Africa. Specifically, the role of myocarditis and the genetic causes of cardiomyopathy are largely unidentified in Africans. Method: The African Cardiomyopathy and Myocarditis Registry Program (the IMHOTEP study) is a pan-African multi-centre, hospital-based cohort study, designed with the primary aim of describing the clinical characteristics, genetic causes, prevalence, management and outcome of cardiomyopathy and myocarditis in children and adults. The secondary aim is to identify barriers to the implementation of evidence-based care and provide a platform for trials and other intervention studies to reduce morbidity and mortality in cardiomyopathy. The registry consists of a prospective cohort of newly diagnosed (i.e., incident) cases and a retrospective (i.e., prevalent) cohort of existing cases from participating centres. Patients with cardiomyopathy and myocarditis will be subjected to a standardized 3-stage diagnostic process. To date, 750 patients have been recruited into the multi-centre pilot phase of the study. Conclusion: The IMHOTEP study will provide comprehensive and novel data on clinical features, genetic causes, prevalence and outcome of African children and adults with all forms of cardiomyopathy and myocarditis in Africa. Based on these findings, appropriate strategies for management and prevention of the cardiomyopathies in LMICs are likely to emerge.
AB - Background: Heart failure (HF), the dominant form of cardiovascular disease in Africans, is mainly due to hypertension, rheumatic heart disease and cardiomyopathy. Cardiomyopathies pose a great challenge because of poor prognosis and high prevalence in low- and middle-income countries (LMICs). Little is known about the etiology and outcome of cardiomyopathy in Africa. Specifically, the role of myocarditis and the genetic causes of cardiomyopathy are largely unidentified in Africans. Method: The African Cardiomyopathy and Myocarditis Registry Program (the IMHOTEP study) is a pan-African multi-centre, hospital-based cohort study, designed with the primary aim of describing the clinical characteristics, genetic causes, prevalence, management and outcome of cardiomyopathy and myocarditis in children and adults. The secondary aim is to identify barriers to the implementation of evidence-based care and provide a platform for trials and other intervention studies to reduce morbidity and mortality in cardiomyopathy. The registry consists of a prospective cohort of newly diagnosed (i.e., incident) cases and a retrospective (i.e., prevalent) cohort of existing cases from participating centres. Patients with cardiomyopathy and myocarditis will be subjected to a standardized 3-stage diagnostic process. To date, 750 patients have been recruited into the multi-centre pilot phase of the study. Conclusion: The IMHOTEP study will provide comprehensive and novel data on clinical features, genetic causes, prevalence and outcome of African children and adults with all forms of cardiomyopathy and myocarditis in Africa. Based on these findings, appropriate strategies for management and prevention of the cardiomyopathies in LMICs are likely to emerge.
KW - Africa
KW - Cardiomyopathy
KW - Cardiovascular outcomes
KW - Genetics
KW - Heart failure
KW - Myocarditis
UR - http://www.scopus.com/inward/record.url?scp=85102065562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102065562&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2021.02.026
DO - 10.1016/j.ijcard.2021.02.026
M3 - Article
C2 - 33607192
AN - SCOPUS:85102065562
SN - 0167-5273
VL - 333
SP - 119
EP - 126
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -